
Our Blog
Targeted Reach, Tighter Relationships: Why Rare Disease Launches Are Different
Drug Channels Institute | January 9, 2026
In this Drug Channels Institute guest post, “Targeted Reach, Tighter Relationships: Why Rare Disease Launches Are Different,” PANTHERx’s Chief Commercial & Clinical Officer, Dr. Richard...
PANTHERx Rare Submits Comment Letter for FDA’s Rare Disease Innovation, Science and Exploration (RISE) Workshop Series
January 5, 2026
Dr. Richard Faris, our Chief Commercial and Clinical Officer, recently submitted a proposal on behalf of PANTHERx in response to the FDA’s request for public...
Dr. Richard Faris, Chief Commercial & Clinical Officer at PANTHERx Rare, elected to the Board of Directors for the National Association of Specialty Pharmacy (NASP)
GlobeNewswire | September 16, 2025
Dr. Richard Faris, PhD, MSc, RPh, will bring his extensive expertise to NASP, helping to guide the organization as it advances specialty pharmacy, promotes innovation,...
New article from PANTHERx CEO, Bansi Nagji, explores how hyper-personalization is reshaping the way we approach rare disease care
Drug Channels Institute | September 12, 2025
Bansi explores how the emerging model of “Rare Pharmacy” addresses the challenges rare diseases pose to patients, caregivers, and the healthcare system. His perspective highlights...
Q1 2022: PANTHERx Earns #1 Ranking in Quarterly MMIT Patient Satisfaction Survey
June 3, 2022
PANTHERx Rare Pharmacy is proud to have again earned the #1 ranking in the quarterly patient satisfaction survey conducted by MMIT, an independent national survey entity....
Q3 2021: PANTHERx Continues to Hold #1 Ranking in Quarterly MMIT Patient Satisfaction Survey
December 10, 2021
This past year has proven to be one of record patient satisfaction scores for PANTHERx Rare. In the first half of 2021, PANTHERx led the...



